Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.

Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W
Cancer Res. 2011 71 (14): 4920-31

PMID: 21613408 · PMCID: PMC3138877 · DOI:10.1158/0008-5472.CAN-10-3879

MeSH Terms (20)

Anaplastic Lymphoma Kinase Animals Brain Cell Line, Tumor Drug Synergism Female Humans Isoenzymes Male Mice Mice, Inbred C57BL Mice, Nude Models, Molecular Neoplasms Point Mutation Protein Kinase Inhibitors Pyridazines Receptor Protein-Tyrosine Kinases Sirolimus TOR Serine-Threonine Kinases

Connections (2)

This publication is referenced by other Labnodes entities:

Links